GlassScriptPhysician profile
Laura A Davide
NPI 1578771895
$10,310.93
in general payments reported to CMS, 2019-2025
32 companies · $1,609 in 2025
The $1,609 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,332 · 2022: $2,447 · 2023: $2,238 · 2024: $2,685 · 2025: $1,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,531.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,588.21 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,948.56 | 2021-2025 | |
| Lundbeck LLC | $1,013.44 | 2022-2025 | Rexulti, Brintellix |
| Amgen INC. | $907.61 | 2021-2025 | Repatha, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $584.47 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $569.84 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $478.27 | 2021-2025 | Trintellix |
| Paratek Pharmaceuticals, INC. | $317.73 | 2021-2024 | Nuzyra |
| Abbott Laboratories | $237.49 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $228.35 | 2021-2025 | Spravato |
| Pfizer INC. | $213.01 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $198.02 | 2023 | |
| Merck Sharp & Dohme LLC | $137.29 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Intuity Medical INC | $123.39 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Intuitive Surgical, INC. | $120.00 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $103.52 | 2024 | Inspire |
| Biohaven Pharmaceuticals, INC. | $72.25 | 2021 | |
| Idorsia Pharmaceuticals US INC | $71.04 | 2023 | Quviviq |
| Ardelyx, INC. | $50.76 | 2024-2025 | Ibsrela |
| Biohaven Pharmaceutical Holding Company LTD. | $44.51 | 2022 | |
| Bausch Health US, LLC | $42.10 | 2021 | |
| Lilly USA, LLC | $40.51 | 2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $30.67 | 2021 | |
| Astellas Pharma US INC | $28.45 | 2025 | Veozah |
| Ars Pharmaceuticals Operations, INC. | $26.46 | 2025 | Neffy |
| Supernus Pharmaceuticals, INC. | $25.09 | 2021 | |
| Sanofi Pasteur INC. | $22.48 | 2023 | |
| Esperion Therapeutics, INC. | $21.67 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.94 | 2024 | Evkeeza |
| Currax Pharmaceuticals LLC | $16.99 | 2025 | Contrave |
| Shield Therapeutics INC | $15.93 | 2023 | Accrufer |
| Vistapharm, INC. | $14.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Davide listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.